Patents Assigned to Xoma Corporation
  • Anti-protozoan methods and materials
    Patent number: 6440936
    Abstract: The present invention relates to methods for treating protozoan infections comprising administering to a subject suffering from protozoan infection, a bacteriocidal/permeability-inducing (BPI) protein product.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: August 27, 2002
    Assignee: Xoma Corporation
    Inventor: Lewis H. Lambert, Jr.
  • Stable bactericidal permeability-increasing protein products and pharmaceutical compositions containing the same
    Patent number: 6433140
    Abstract: Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and state homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and in sequelae.
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: August 13, 2002
    Assignee: XOMA Corporation
    Inventors: Georgia Theofan, Arnold Horwitz, David Burke, Manik Baltaian, Lynn Grinna
  • Therapeutic uses of BPI protein products for human meningococcemia
    Publication number: 20020103114
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Application
    Filed: November 30, 2000
    Publication date: August 1, 2002
    Applicant: XOMA Corporation and The Board of Regents, The University of Texas System
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Treatment of Mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
    Publication number: 20020103118
    Abstract: The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.
    Type: Application
    Filed: February 13, 2001
    Publication date: August 1, 2002
    Applicant: XOMA Corporation
    Inventor: Lewis H. Lambert
  • Human therapeutic uses of BPI Protein products
    Publication number: 20020094952
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Application
    Filed: December 8, 2000
    Publication date: July 18, 2002
    Applicant: XOMA Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J.H. van Deventer, Marijke A.M. von der Mohlen, Nancy Wedel
  • Therapeutic uses of bactericidal/permeability increasing (BPI) protein products
    Publication number: 20020090368
    Abstract: The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.
    Type: Application
    Filed: August 27, 2001
    Publication date: July 11, 2002
    Applicant: XOMA Corporation
    Inventor: Roger G. Little
  • Anti-fungal peptides
    Publication number: 20020077298
    Abstract: The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and therapeutic uses of such peptides.
    Type: Application
    Filed: June 14, 2001
    Publication date: June 20, 2002
    Applicant: XOMA Corporation
    Inventors: Roger G. Little, Edward Lim, Mitchell B. Fadem
  • Lipopolysaccharide binding protein derivatives
    Patent number: 6376462
    Abstract: Disclosed are novel biologically active lipopolysaccharide binding protein (LBP) derivatives including LBP derivative hybrid proteins which are characterized by the ability to bind to and neutralize LPS and which lack the CD14-mediated immunostimulatory properties of holo-LBP.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: April 23, 2002
    Assignee: Xoma Corporation
    Inventors: Héle{overscore (n)}e Gazzano-Santoro, Georgia Theofan, Patrick W. Trown
  • Uses of lipopolysaccharide binding protein
    Patent number: 6306824
    Abstract: Novel LBP compositions and therapeutic uses for LBP are provided for preventing the adverse effects of exposure to endotoxin.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: October 23, 2001
    Assignee: Xoma Corporation
    Inventors: Russell L. Dedrick, Stephen F. Carroll
  • Anti-protozoan methods and materials
    Publication number: 20010029245
    Abstract: The present invention relates to methods for treating protozoan infections comprising administering to a subject suffering from protozoan infection. a bacteriocidal/permeability-inducing (BPI) protein product.
    Type: Application
    Filed: June 8, 2001
    Publication date: October 11, 2001
    Applicant: XOMA Corporation
    Inventor: Lewis H. Lambert
  • Therapeutic uses of bactericidal/permeability-increasing protein dimer products
    Patent number: 6277821
    Abstract: Improved therapeutic compositions, methods and uses of bactericidal/permeability-increasing protein (BPI) products involve use of dimeric forms of BPI protein product monomers characterized by enhanced in vivo biological activity. Preferred formulations include 50 percent or more by weight dimeric product and preferred therapeutic uses include endotoxin neutralization and heparin neutralization.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: August 21, 2001
    Assignee: Xoma Corporation
    Inventors: William Steve Ammons, Roger G. Little
  • Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
    Patent number: 6274344
    Abstract: The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: August 14, 2001
    Assignee: XOMA Corporation
    Inventor: Marc D. Better
  • Methods for the preparation of positively charged proteins
    Patent number: 6274348
    Abstract: Disclosed are novel hybrid fusion proteins comprising at their amino terminus, bactericidal/permeability-increasing protein or a biologically active fragment thereof and, at their carboxy terminus, at least one immunoglobulin heavy chain constant domain useful in treating bacterial infection. Also disclosed are DNA sequences encoding such proteins, recombinant methods for production of the proteins, and pharmaceutical preparations containing the recombinant products.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: August 14, 2001
    Assignee: XOMA Corporation
    Inventor: Lynn Grinna
  • Method for quantifying LBP in body fluids
    Patent number: 6274328
    Abstract: The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: August 14, 2001
    Assignee: Xoma Corporation
    Inventors: Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-kuen Ma
  • Anti-protozoan methods and materials
    Patent number: 6271203
    Abstract: The present invention relates to methods for treating protozoan infections comprising administering to a subject suffering from protozoan infection, a bacteriocidal/permeability-inducing (BPI) protein product.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: August 7, 2001
    Assignee: Xoma Corporation
    Inventor: Lewis H. Lambert, Jr.
  • Bactericidal/permeability-increasing protein (BPI) compositions
    Patent number: 6268345
    Abstract: Bactericidal/permeability increasing protein (BPI) and biologically active fragments, analogs and variants thereof are solubilized by lipid carriers including phospholipids, liposomes and nonionic detergents and stabilized against particle formation by poloxamer surfactants.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: July 31, 2001
    Assignee: Xoma Corporation
    Inventor: Lynn S. Grinna
  • Pharmaceutical composition
    Patent number: 6255284
    Abstract: Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, biologically active analogs of BPI, and biologically active variants of BPI.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: July 3, 2001
    Assignee: Xoma Corporation
    Inventors: Weldon Courtney McGregor, James Stubstad, C. Paul Chang
  • Therapeutic uses of BPI protein products for human meningococcemia
    Patent number: 6242418
    Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: June 5, 2001
    Assignees: Xoma Corporation, The Board of Regents, The University of Texas System
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
    Patent number: 6228834
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Grant
    Filed: June 8, 1998
    Date of Patent: May 8, 2001
    Assignee: Xoma Corporation
    Inventor: Roger G. Little, II
  • Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
    Patent number: 6214789
    Abstract: The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.
    Type: Grant
    Filed: April 1, 1996
    Date of Patent: April 10, 2001
    Assignee: Xoma Corporation
    Inventor: Lewis H. Lambert, Jr.